Bioventus (NASDAQ:BVS) Issues FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.750-0.790 for the period, compared to the consensus EPS estimate of 0.770. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $605.1 million.

Bioventus Stock Performance

Shares of BVS traded up $0.06 during mid-day trading on Friday, reaching $14.04. The company’s stock had a trading volume of 603,101 shares, compared to its average volume of 530,261. Bioventus has a 1-year low of $6.26 and a 1-year high of $15.89. The stock has a market cap of $1.17 billion, a P/E ratio of 18.27, a PEG ratio of 1.94 and a beta of 0.63. The business has a 50-day simple moving average of $10.70 and a two-hundred day simple moving average of $9.66. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. The business had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 29.77% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities research analysts anticipate that Bioventus will post 0.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Tuesday, June 16th. Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Craig Hallum reaffirmed a “buy” rating and issued a $18.00 target price on shares of Bioventus in a report on Thursday. Finally, Barrington Research set a $18.00 price target on Bioventus in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Bioventus has an average rating of “Buy” and an average price target of $16.25.

Institutional Investors Weigh In On Bioventus

A number of hedge funds have recently added to or reduced their stakes in BVS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Bioventus by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock valued at $1,486,000 after purchasing an additional 26,103 shares during the last quarter. Legal & General Group Plc grew its stake in Bioventus by 100.9% in the 2nd quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock valued at $473,000 after buying an additional 35,873 shares in the last quarter. Rhumbline Advisers grew its position in shares of Bioventus by 20.6% in the second quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock valued at $431,000 after purchasing an additional 11,133 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Bioventus by 32.5% in the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock worth $1,401,000 after purchasing an additional 51,951 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.